Comments
# As child vaccines become a point of discussion, Bharat Biotech’s Covaxin undertakes trials for paediatric doses .
# And more to add to the arsenal, now Novavax claims efficacy against variants . And that injects a shot of good news into India’s Covid-prevention programme.
# Capillary Leak syndrome: The European regulator EMA asks for additional side-effect labelling on the AZ-Oxford vaccine. Point to note, this is the vaccine that is being rolled out in India, made here by Serum Institute.
# Two Indians are now on CEPI’s scientific advisory board .
# One dose will do? Well, a local study explores the option being touted by experts in India and overseas.
# A start-up from Pune comes up with 3D-printed masks . The need for them will continue for sometime, despite the vaccination drive.
# And more oxygen plants are being set up across the country. The second wave brought home the distressing message of shortages, never to be repeated.
(eom)
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.